Robert W. Tuman

JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia

Carl L. Manthey, Dana L. Johnson, Carl R. Illig et al. · Molecular Cancer Therapeutics · 2009 · 107 citations

Medicine, Oncology, Pharmacology +17

R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies

Janine Arts, Patrick Angibaud, Ann Mariën et al. · British Journal of Cancer · 2007 · 89 citations · Full text

Medicine, Oncology, Pharmacology +15

Comparison and Effects of Natural and Synthetic Glucose Tolerance Factor in Normal and Genetically Diabetic Mice

Robert W. Tuman, James T Bilbo, Richard J. Doisy · Diabetes · 1978 · 73 citations

Life Sciences, Biochemistry, Food Science +14

Carbohydrate biguanides as potential hypoglycemic agents.

Allen B. Reitz, Robert W. Tuman, Carol S. Marchione et al. · Journal of Medicinal Chemistry · 1989 · 59 citations

Life Sciences, Medicinal Chemistry, Pharmacology +9

Studies with an Orally Bioavailable αV Integrin Antagonist in Animal Models of Ocular Vasculopathy: Retinal Neovascularization in Mice and Retinal Vascular Permeability in Diabetic Rats

Rosemary J. Santulli, William A. Kinney, Shyamali Ghosh et al. · Journal of Pharmacology and Experimental Therapeutics · 2007 · 59 citations

Medicine, Ophthalmology, Pharmacology +14